{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:21:27Z","timestamp":1787840487869,"version":"build-2784847793"},"reference-count":7,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 2","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>\n                    A\n                    <jats:sc>BSTRACT<\/jats:sc>\n                  <\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Preeclampsia (PE) is a significant hypertensive disorder of pregnancy contributing to maternal and neonatal morbidity and mortality. Early detection and intervention are crucial to reducing the burden of this disease. Glycosylated fibronectin (GlyFn) has emerged as a potential biomarker for the early prediction of PE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>A prospective cohort study was conducted in the Department of Obstetrics and Gynaecology at MGM Medical College and MTH Hospital, Indore. A total of 140 pregnant women with risk factors for PE were enrolled between December 2022 and March 2023. Serum GlyFn levels were measured using an ELISA-based method. Participants were categorized based on GlyFn levels into normal (&lt;250 \u03bcg\/mL), and positive groups (250\u2013350 \u03bcg\/mL, 350\u2013500 \u03bcg\/mL, &gt;500 \u03bcg\/mL). GlyFn levels were monitored every 4 weeks, and clinical outcomes, including PE onset, maternal complications, and fetal outcomes, were analyzed. Statistical analysis was performed using ANOVA, Pearson correlation, and Chi-square tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The majority of participants were nulliparous (33.3%), with a mean age of 24.3 years. Elevated GlyFn levels (&gt;250 \u03bcg\/mL) were significantly associated with the development of PE (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; .001). The sensitivity, specificity, positive predictive value, and negative predictive value of GlyFn at a cutoff of 250 \u03bcg\/mL were 92.3, 88.9, 96, and 80%, respectively. The average gestational age (GA) at GlyFn positivity was inversely correlated with the GA at PE onset, with early detection providing a larger intervention window. Maternal complications included postpartum hemorrhage (21.44%) and thrombocytopenia (15%), while fetal complications included preterm birth (23.65%) and intrauterine growth restriction (9.3%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Serum GlyFn is a promising biomarker for early prediction of PE, enabling timely interventions to improve maternal and fetal outcomes. A GlyFn cutoff of 250 \u03bcg\/mL showed high diagnostic accuracy. Further research is required to validate its clinical utility and integrate it into routine antenatal care.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jpbs.jpbs_277_25","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T01:01:13Z","timestamp":1750208473000},"page":"S1710-S1712","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["A Prospective Cohort Study on Serum Glycosylated Fibronectin as a Biomarker for Early Prediction of Preeclampsia"],"prefix":"10.4103","volume":"17","author":[{"given":"Vibhuti","family":"Thakur","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynaecology, MGM, Medical College, Indore, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Kavyashree","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, MGM, Medical College, Indore, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poonam","family":"Mathur","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, MGM, Medical College, Indore, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"key":"R1-20250618","first-page":"856","article-title":"Study on maternal biomarkers in preeclampsia","volume":"38","author":"Nagalla","year":"2012","journal-title":"J Obstet Gynaecol Res"},{"key":"R2-20250618","first-page":"93","article-title":"Diagnostic performance of glycosylated fibronectin in women with suspected preeclampsia","volume":"175","author":"Huhn","year":"2014","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R3-20250618","first-page":"1141","article-title":"Glycosylated fibronectin as a first-trimester biomarker for prediction of preeclampsia","volume":"125","author":"Rasanen","year":"2015","journal-title":"Obstet Gynecol"},{"key":"R4-20250618","first-page":"961","article-title":"Maternal and fetal outcomes in preeclampsia: A cross-sectional study","volume":"29","author":"Choudhary","year":"2018","journal-title":"Indian J Clin Pract"},{"key":"R5-20250618","first-page":"i3951","article-title":"Clinical risk factors for pre-eclampsia determined in early pregnancy: Systematic review and meta-analysis of large cohort studies","volume":"354","author":"Bartsch","year":"2016","journal-title":"BMJ"},{"key":"R6-20250618","first-page":"S21","article-title":"Inflammatory pathways in preeclampsia: The role of oxidative stress and placental dysfunction","volume":"33","author":"Myatt","year":"2012","journal-title":"Placenta"},{"key":"R7-20250618","first-page":"181","article-title":"Diagnosis and management of gestational hypertension and preeclampsia","volume":"102","author":"Sibai","year":"2003","journal-title":"Obstet Gynecol"}],"container-title":["Journal of Pharmacy and Bioallied Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.jpbs_277_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:23:51Z","timestamp":1787837031000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jpbs.jpbs_277_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":7,"journal-issue":{"issue":"Suppl 2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/jpbs.jpbs_277_25","relation":{},"ISSN":["0976-4879","0975-7406"],"issn-type":[{"value":"0976-4879","type":"print"},{"value":"0975-7406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"2025-01-29","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}